Close Menu

Almac

Almac will run AclarusDx on the Affymetrix Dx2 platform. The test is based on Exonhit's proprietary biochip, a customized Affy GeneChip called the Genome Wide SpliceArray.

Paris-based Exonhit has already introduced AclarusDx to the French market and is planning to launch it in the wider European market.

Almac will analyze all samples performed with Exonhit's blood-based AclarusDx test.

Affymetrix, Almac Diagnostics, and Oxford Gene Technology are among the firms that have been awarded funding to develop new approaches for tumor profiling and data capture.

Almac researchers and academic collaborators used the company's Disease Specific Array platform to identify biomarkers associated with ovarian and breast cancer.

Almac, headquartered in Craigavon, Northern Ireland, said the new CLIA-registered lab supports its biomarker discovery and development strategy by "enabling the use of novel tests to stratify and enrich prospective clinical trials."

The firm said the lab will support its own needs as well as those of its pharmaceutical partners.

BioFocus has launched an FLT screening and profiling service using Almac's Flexyte assay platform and is offering services against targets such as proteases, phosphatases, and kinases.

Skyline Diagnostics' AMLprofiler leukemia test recently became the fourth Affy-based test to hit the market. Some of the company's other diagnostic partners, however, have changed their development strategies since the "Powered by Affymetrix" program was launched.

The firm will offer a range of customizable bioinformatics and biostatistics solutions to help with biomarker discovery and development, exploratory analysis, mechanistic and functional analysis, traditional and next-generation sequencing data analysis, biostatistics, and data integration.

Pages

Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.

The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.

Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.

In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.